B. Riley Forecasts Harrow’s Q2 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Equities researchers at B. Riley reduced their Q2 2025 earnings estimates for shares of Harrow in a research report issued on Monday, March 31st. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of $0.17 for the quarter, down from their previous estimate of $0.25. B. Riley currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s Q3 2025 earnings at $0.21 EPS and Q4 2025 earnings at $0.38 EPS.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Thursday, March 27th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million.

Separately, HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Harrow in a report on Monday.

Harrow Trading Down 6.1 %

HROW opened at $24.98 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23. The stock has a market cap of $889.66 million, a PE ratio of -26.57 and a beta of 0.69. The business has a 50 day moving average of $28.53 and a 200-day moving average of $37.72.

Institutional Trading of Harrow

Hedge funds have recently made changes to their positions in the stock. Braidwell LP raised its stake in Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company’s stock valued at $30,431,000 after buying an additional 467,401 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after acquiring an additional 194,480 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Harrow by 195.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after acquiring an additional 166,602 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Harrow by 483.2% in the 4th quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock worth $5,044,000 after purchasing an additional 124,574 shares during the last quarter. Finally, Neuberger Berman Group LLC boosted its stake in Harrow by 128.0% in the 4th quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company’s stock worth $6,728,000 after purchasing an additional 112,588 shares in the last quarter. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.